从50年代至今,癌症的化学疗法由于抗癌剂的有效利用而取得了很大进步,但大多数发生在主要脏器的实体癌仍然是难治的,特别是象发生率很高的各种消化道癌和发生率正逐渐上升的肺非小细胞癌等疗效很差的癌也不少见。临床上应用化疗,对小儿癌症和造血系统肿瘤已取得了疗效,人们期望对其他癌症也能如此,为此,世界各国都在致力于抗癌剂的研制。一、新抗癌剂的研制现在进入临床Ⅰ、Ⅱ期试验的化合物中研制的主要目标是氟化嘧啶类化合物、蒽环类化合物、铂络合物等。本文就其中几个代表性例子 Since the 1950s, cancer chemotherapy has made great progress due to the effective use of anti-cancer agents, but most solid cancers that occur in major organs remain intractable, especially in areas where the incidence is high. Gastrointestinal cancer and the incidence of non-small cell lung cancer, which is gradually increasing in incidence, are also not uncommon. The clinical application of chemotherapy has already yielded therapeutic effects on pediatric cancers and hematopoietic system tumors. It is expected that this can be done for other cancers. For this reason, all countries in the world are working on the development of anticancer agents. First, the development of new anti-cancer agents Now entering the clinical phase I, phase II trials of compounds in the development of the main target is fluorinated pyrimidines, anthracyclines, platinum complexes. Here are some representative examples